Xeris Biopharma Holdings, Inc.

NasdaqGS:XERS Stock Report

Market Cap: US$497.7m

Xeris Biopharma Holdings Balance Sheet Health

Financial Health criteria checks 2/6

Xeris Biopharma Holdings has a total shareholder equity of $-19.3M and total debt of $230.5M, which brings its debt-to-equity ratio to -1195.1%. Its total assets and total liabilities are $331.7M and $351.0M respectively.

Key information

-1,195.1%

Debt to equity ratio

US$230.48m

Debt

Interest coverage ration/a
CashUS$77.57m
Equity-US$19.29m
Total liabilitiesUS$351.02m
Total assetsUS$331.73m

Recent financial health updates

No updates

Recent updates

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Oct 25

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks

Sep 07
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Jun 04
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Rockets 30% But Many Are Still Ignoring The Company

Xeris Biopharma: Checking-In On One Of My 'Top Ideas'

Mar 30

Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Mar 09
Analysts Are Updating Their Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Estimates After Its Full-Year Results

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Mar 06
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shares Climb 26% But Its Business Is Yet to Catch Up

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Jan 05
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Fly 32% But Investors Aren't Buying For Growth

Xeris Pharmaceuticals Q2 2022 Earnings Preview

Aug 09

Xeris amends commercial terms for hypoglycemia therapy as partner inks buyout deal

Aug 01

Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven

May 21

Xeris Continues To Execute And Build Long-Term Value Potential

Feb 22

Xeris Biopharma: Market Is Snubbing The Strongbridge Acquisition

Dec 20

Financial Position Analysis

Short Term Liabilities: XERS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: XERS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: XERS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: XERS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XERS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: XERS has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 0.4% each year


Discover healthy companies